Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X FTSE Southeast Asia ETF (ASEA) vs Novartis AG (NVS) Price & Performance

Global X FTSE Southeast Asia ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Global X FTSE Southeast Asia ETF vs Novartis AG — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.47, while Novartis AG trades at $152.89 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.

ASEANVS
Sector
Sector/ThematicHealth
52-Week High
$21.53$168.62
52-Week Low
$16.86$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X FTSE Southeast Asia ETF

No Aura AI signal available yet.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X FTSE Southeast Asia ETF

ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.

Read more on ASEA

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS